Screener
Cytokinetics CYTK Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:DeferredRevenueCurrent.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Short-term operating lease liabilities | 21,042 | 19,111 |
| Current portion of convertible and long-term debt | 27,358 | 41,181 |
| Derivative liabilities measured at fair value | 30,700 | 31,100 |
| Deferred revenue | 1,653 | 1,612 |
| Other current liabilities | 3,304 | 3,833 |
| Total current liabilities | 181,429 | 202,452 |
| Term loans, net | 248,202 | 246,384 |
| Convertible notes, net | 871,527 | 869,597 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's deferred revenue?
- Cytokinetics (CYTK) reported deferred revenue of $1.65M in Q2 2026.
- How has Cytokinetics's deferred revenue changed year-over-year?
- Cytokinetics's deferred revenue increased by 23.0% year-over-year, from $1.34M to $1.65M.
- What is the long-term trend for Cytokinetics's deferred revenue?
- Over 5 years (2020 to 2025), Cytokinetics's deferred revenue has grown at a -55.0% compound annual growth rate (CAGR), from $87M to $1.61M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Cytokinetics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude